Who is sponsoring NCT00784732?

NCT00784732 is sponsored by Novartis.

What condition does NCT00784732 study?

NCT00784732 studies Seasonal Allergic Rhinitis.

What drugs are being tested in NCT00784732?

Interventions: QAV680, QAV680, Mometasone Furoate.

What is the status of NCT00784732?

NCT00784732 is currently COMPLETED.

Last reviewed 2016-11-16 · How we verify

A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model

NCT00784732 Phase 2 COMPLETED

This study will compare the effectiveness of QAV680 against placebo in treating the symptoms of seasonal allergic rhinitis in an Environmental Exposure Chamber.

Details

Lead sponsor	Novartis
Phase	Phase 2
Status	COMPLETED
Enrolment	44
Start date	2008-09
Completion	2008-12

Conditions

Seasonal Allergic Rhinitis

Interventions

QAV680
QAV680
Mometasone Furoate

Primary outcomes

Total Nasal Symptom Score (TNSS) over the last 2 hours of exposure in the EEC Percentage nasal lavage eosinophil count post EEC — TNSS: 6-8h during EEC exposure on Day 10

Countries

Canada